Imugene Management

Management criteria checks 1/4

Imugene's CEO is Leslie Chong, appointed in Nov 2016, has a tenure of 7.67 years. total yearly compensation is A$2.48M, comprised of 30.2% salary and 69.8% bonuses, including company stock and options. directly owns 1.17% of the company’s shares, worth A$5.06M. The average tenure of the management team and the board of directors is 1.4 years and 5.8 years respectively.

Key information

Leslie Chong

Chief executive officer

AU$2.5m

Total compensation

CEO salary percentage30.2%
CEO tenure7.7yrs
CEO ownership1.2%
Management average tenure1.4yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Apr 12
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Sep 19
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

May 30
We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Jan 30
Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Nov 11
Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Aug 22
Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Feb 28
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

A Look At Imugene's (ASX:IMU) CEO Remuneration

Feb 17
A Look At Imugene's (ASX:IMU) CEO Remuneration

Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Dec 24
Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

CEO Compensation Analysis

How has Leslie Chong's remuneration changed compared to Imugene's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-AU$89m

Sep 30 2023n/an/a

-AU$64m

Jun 30 2023AU$2mAU$750k

-AU$38m

Mar 31 2023n/an/a

-AU$39m

Dec 31 2022n/an/a

-AU$40m

Sep 30 2022n/an/a

-AU$39m

Jun 30 2022AU$1mAU$600k

-AU$38m

Mar 31 2022n/an/a

-AU$33m

Dec 31 2021n/an/a

-AU$27m

Sep 30 2021n/an/a

-AU$23m

Jun 30 2021AU$789kAU$408k

-AU$18m

Mar 31 2021n/an/a

-AU$15m

Dec 31 2020n/an/a

-AU$12m

Sep 30 2020n/an/a

-AU$11m

Jun 30 2020AU$733kAU$375k

-AU$11m

Mar 31 2020n/an/a

-AU$10m

Dec 31 2019n/an/a

-AU$9m

Sep 30 2019n/an/a

-AU$8m

Jun 30 2019AU$777kAU$350k

-AU$8m

Mar 31 2019n/an/a

-AU$7m

Dec 31 2018n/an/a

-AU$6m

Sep 30 2018n/an/a

-AU$5m

Jun 30 2018AU$403kAU$300k

-AU$4m

Compensation vs Market: Leslie's total compensation ($USD1.68M) is above average for companies of similar size in the Australian market ($USD620.88K).

Compensation vs Earnings: Leslie's compensation has increased whilst the company is unprofitable.


CEO

Leslie Chong

7.7yrs

Tenure

AU$2,482,687

Compensation

Ms. Leslie Chong served as Non-Executive Director of Chimeric Therapeutics Limited since August 28, 2020 until July 2023. Ms. Chong has been the Chief Executive Officer of Imugene Limited since November 21...


Leadership Team

NamePositionTenureCompensationOwnership
Paul Hopper
Executive Chairman11.8yrsAU$515.23k5.57%
A$ 24.1m
Leslie Chong
CEO, MD & Executive Director7.7yrsAU$2.48m1.17%
A$ 5.1m
Michael Tonroe
CFO & Company Secretary1.8yrsAU$839.00kno data
Nicholas Ede
Head of Corporate Developmentless than a yearAU$874.91k0.24%
A$ 1.0m
Monil Shah
Chief Business Officer3.1yrsAU$799.20kno data
Bradley Glover
Chief Operating Officerless than a yearno datano data
Ursula McCurry
Senior Vice President of Clinical Operations2.5yrsno datano data
John Byon
Senior Vice President of Clinical Developmentless than a yearno datano data
Joseph Woodard
Chief Medical Officerless than a yearno datano data

1.4yrs

Average Tenure

57yo

Average Age

Experienced Management: IMU's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Paul Hopper
Executive Chairman11.8yrsAU$515.23k5.57%
A$ 24.1m
Leslie Chong
CEO, MD & Executive Director6.3yrsAU$2.48m1.17%
A$ 5.1m
Jens Eckstein
Independent Non-Executive Director5.2yrsAU$115.52k0.29%
A$ 1.2m
Kimberlee Drapkin
Non-Executive Director1.1yrsAU$2.08k0.0050%
A$ 21.8k
Yuman Fong
Chair of Oncolytic Virotherapy Scientific Advisory Board4.7yrsno datano data
Ursula Wiedermann
Member of Scientific Advisory Boardno datano datano data
Neil Segal
Member of Scientific Advisory Board10.3yrsno datano data
Josep Tabernero Caturla
Member of Scientific Advisory Board5.8yrsno datano data
Yelena Janjigian
Scientific Advisory Board Member8.3yrsno datano data
Peter Schmid
Member of Scientific Advisory Board6.6yrsno datano data
Tanios Bekaii-Saab
Member of Scientific Advisory Board5.8yrsno datano data
Pravin T. Kaumaya
Member of Scientific Advisory Board5.8yrsno datano data

5.8yrs

Average Tenure

Experienced Board: IMU's board of directors are considered experienced (5.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.